OBJECTIVES: Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is an effective and well-tolerated therapy in patients with type 2 diabetes mellitus (T2DM) in clinical trials. The objective of this study was to evaluate the impact of CANA on glycemic control in a real-world population.  METHODS: A retrospective cohort analysis of adult patients with T2DM was conducted using 2013 data from the Inovalon MORERegistry, which consists of commercial, managed Medicare and Medicaid medical, pharmacy and laboratory claims.  Patients with T2DM ≥18 years of age with ≥60 days of canagliflozin supply and HbA1c test results within 120 days pre- and ≥60 days post their first observed canagliflozin prescription fill were included.  Patients with other types of diabetes, enrollment gaps and missing data were excluded.  The difference between HbA1c levels pre- and post-canagliflozin was measured by a paired-t test.  A subgroup analysis of patients with HbA1c>7% at baseline was also conducted. RESULTS: Of the 268 patients eligible patients with a claim for canagliflozin in 2013, 70% of patients received a 100mg dose.  Median follow-up time to HbA1c measurement was 106 days.  Mean (SD) age was 56.8 yrs (8.7), and 57% were male.  The majority of the patients (63%) were covered by commercial payers.  Mean HbA1c pre-canagliflozin was 8.3% (95% CI: 8.2%, 8.5%) and post-canagliflozin was 7.6% (95% CI: 7.5%, 7.8%).  Mean difference in HbA1c pre-post was 0.7% (p<0.001).  In the subset of patients with HbA1c>7% at baseline (81%), the mean difference pre-post canagliflozin was 0.9% (95% CI: 0.8%, 1.1%), p<0.001. CONCLUSIONS: In a real-world setting, patients with T2DM had improved glycemic control as measured by HbA1c after receiving canagliflozin.  HbA1c lowering in patients with baseline HbA1c>7% was similar to the HbA1c improvement for all adults.  The HbA1c results were generally similar to those observed in clinical trials.